14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MAIA vs SNY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MAIA carries a Unified Composite Score of 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin), whereas SNY carries 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin).
Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both MAIA (37.6/100 SELL) and SNY (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MAIA vs SNY. Trailing 12-month operating profitability (MAIA 0.0% vs SNY 22.3%) and valuation multiples (MAIA 1.2x vs SNY 8.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SNY Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $110.6B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment52.0% of Rev ($15.6B)
90D Engineering Disclosures0 Published
Investor FAQ MAIA vs SNY Key Questions & Quantitative Answers
As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MAIA carries a Unified Composite Score of 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin), whereas SNY carries 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin). Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both MAIA (37.6/100 SELL) and SNY (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SNY leads the Growth & Scale pillar: MAIA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SNY at +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.1B TTM revenue (74.3% gross margin, 22.3% operating margin). On trailing 12-month operating scale, MAIA generates N/A in USD-normalized revenue versus $30.1B for SNY. In operating R&D and SG&A reinvestment, MAIA deploys N/A (0 90-day corporate R&D disclosures) versus 52.0% of Rev ($15.6B) (0 disclosures) for SNY.
MAIA screens cheaper on headline valuation multiples. MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SNY trades at 8.6x Forward P/E, 22.9x Trailing P/E, 2.90x PEG, and 3.7x EV/Revenue (29.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MAIA (-341.5% ROE) versus SNY (5.7% ROE) capital efficiency.
In options market volatility and institutional positioning, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk). By comparison, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.20β · 26% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.